Clinical Development

© Getty Images

Artax announces first patient dosed in psoriasis treatment trial

By Isabel Cameron

Artax Biopharma, a clinical-stage biotech company focused on transforming the treatment of autoimmune diseases, has dosed the first patient in its phase 2a trial evaluating oral, small molecule, AX-158 for the treatment of psoriasis.

Follow us